Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.62 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5272877 | 1.00 | UGT2B17 (0.62) | UGT2B17KDM4CSIGMAR1CYP11B1CYP11B2 | |
| SCHEMBL703510 | 1.00 | UGT2B17 (0.62) | UGT2B17KDM4CSIGMAR1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL1976240 | 0.98 | UGT2B17 (0.61) | UGT2B17KDM4CSIGMAR1CYP11B1CYP11B2 | |
| SCHEMBL13114074 | 0.90 | UGT2B17 (0.55) | UGT2B17KDM4CSIGMAR1CYP11B1CYP11B2 | |
| SCHEMBL6799194 | 0.77 | UGT2B17 (1.00) | UGT2B17KDM4CSIGMAR1CYP11B1CYP11B2 | |
| SCHEMBL15825377 | 0.77 | UGT2B17 (0.57) | UGT2B17KDM4CSIGMAR1ADRA1A | |
| SCHEMBL22222496 | 0.74 | UGT2B17 (0.64) | UGT2B17KDM4CSIGMAR1PSMB5HRH3 | |
| SCHEMBL1150666 | 0.73 | ADRA2A (0.43) | UGT2B17CYP11B1CYP11B2ACHEADRA1A | |
| SCHEMBL3585626 | 0.73 | ADRA2A (0.43) | UGT2B17CYP11B1CYP11B2ACHEADRA1A | |
| SCHEMBL15287102 | 0.73 | UGT2B17 (0.57) | UGT2B17KDM4CSIGMAR1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | UGT2B17 2302/4885KDM4C 3493/4885SIGMAR1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.